Nxera Pharma Statistics
Total Valuation
Nxera Pharma has a market cap or net worth of JPY 153.54 billion. The enterprise value is 188.88 billion.
Important Dates
The last earnings date was Friday, October 30, 2026.
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nxera Pharma has 91.39 million shares outstanding. The number of shares has increased by 0.77% in one year.
| Current Share Class | 91.39M |
| Shares Outstanding | 91.39M |
| Shares Change (YoY) | +0.77% |
| Shares Change (QoQ) | +10.88% |
| Owned by Insiders (%) | 9.20% |
| Owned by Institutions (%) | 24.32% |
| Float | 75.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 32.10 |
| PS Ratio | 4.49 |
| PB Ratio | 2.49 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 31.81 |
| P/OCF Ratio | 28.46 |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
The stock's EV/EBITDA ratio is 39.49, with an EV/FCF ratio of 38.86.
| EV / Earnings | n/a |
| EV / Sales | 5.49 |
| EV / EBITDA | 39.49 |
| EV / EBIT | n/a |
| EV / FCF | 38.86 |
Financial Position
The company has a current ratio of 2.56, with a Debt / Equity ratio of 0.81.
| Current Ratio | 2.56 |
| Quick Ratio | 1.71 |
| Debt / Equity | 0.81 |
| Debt / EBITDA | 10.47 |
| Debt / FCF | 10.36 |
| Interest Coverage | 0.09 |
Financial Efficiency
Return on equity (ROE) is -8.31% and return on invested capital (ROIC) is 0.61%.
| Return on Equity (ROE) | -8.31% |
| Return on Assets (ROA) | 0.28% |
| Return on Invested Capital (ROIC) | 0.61% |
| Return on Capital Employed (ROCE) | 0.54% |
| Weighted Average Cost of Capital (WACC) | 6.95% |
| Revenue Per Employee | 113.09M |
| Profits Per Employee | -17.18M |
| Employee Count | 314 |
| Asset Turnover | 0.26 |
| Inventory Turnover | 0.59 |
Taxes
| Income Tax | -155.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +103.14% in the last 52 weeks. The beta is 0.31, so Nxera Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.31 |
| 52-Week Price Change | +103.14% |
| 50-Day Moving Average | 1,365.40 |
| 200-Day Moving Average | 1,069.50 |
| Relative Strength Index (RSI) | 65.27 |
| Average Volume (20 Days) | 2,327,640 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Nxera Pharma had revenue of JPY 35.51 billion and -5.39 billion in losses. Loss per share was -59.39.
| Revenue | 35.51B |
| Gross Profit | 29.19B |
| Operating Income | 617.00M |
| Pretax Income | -5.55B |
| Net Income | -5.39B |
| EBITDA | 4.96B |
| EBIT | 617.00M |
| Loss Per Share | -59.39 |
Full Income Statement Balance Sheet
The company has 16.61 billion in cash and 51.96 billion in debt, with a net cash position of -35.34 billion or -386.73 per share.
| Cash & Cash Equivalents | 16.61B |
| Total Debt | 51.96B |
| Net Cash | -35.34B |
| Net Cash Per Share | -386.73 |
| Equity (Book Value) | 64.15B |
| Book Value Per Share | 701.96 |
| Working Capital | 24.00B |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was 5.60 billion and capital expenditures -590.00 million, giving a free cash flow of 5.01 billion.
| Operating Cash Flow | 5.60B |
| Capital Expenditures | -590.00M |
| Depreciation & Amortization | 4.35B |
| Net Borrowing | -16.04B |
| Free Cash Flow | 5.01B |
| FCF Per Share | 54.85 |
Full Cash Flow Statement Margins
Gross margin is 82.20%, with operating and profit margins of 1.74% and -15.19%.
| Gross Margin | 82.20% |
| Operating Margin | 1.74% |
| Pretax Margin | -15.62% |
| Profit Margin | -15.19% |
| EBITDA Margin | 13.97% |
| EBIT Margin | 1.74% |
| FCF Margin | 14.12% |
Dividends & Yields
Nxera Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.77% |
| Shareholder Yield | -0.77% |
| Earnings Yield | -3.53% |
| FCF Yield | 3.14% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Analyst Forecast
The average price target for Nxera Pharma is 1,975.00, which is 17.56% higher than the current price. The consensus rating is "Buy".
| Price Target | 1,975.00 |
| Price Target Difference | 17.56% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 19.15% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on June 27, 2018. It was a forward split with a ratio of 4.
| Last Split Date | Jun 27, 2018 |
| Split Type | Forward |
| Split Ratio | 4 |
Scores
Nxera Pharma has an Altman Z-Score of 1.16 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.16 |
| Piotroski F-Score | 6 |